Background: Vertebrate oocytes are arrested at second meiotic metaphase by cytostatic factor (CSF) while awaiting fertilization. Accumulating evidence has suggested that inhibition of the anaphase-promoting complex/cyclosome (APC/C) is responsible for this arrest. Xenopus polo-like kinase 1 (Plx1) is required for activation of the APC/C at the metaphase-anaphase transition, and calcium elevation, upon fertilization/activation of eggs, acting through calmodulin-dependent kinase II (CaMKII) is sufficient to activate the APC/C and terminate CSF arrest. However, connections between the Plx1 pathway and the CaMKII pathway have not been identified. Results: Overexpression of Plx1 causes CSF release in the absence of calcium, and depletion of Plx1 from egg extracts blocks induction of CSF release by calcium and CaMKII. Prior phosphorylation of the APC/C inhibitor XErp1/Emi2 by CaMK II renders it a good substrate for Plx1, and phosphorylation by both kinases together promotes its degradation in egg extracts. The pathway is enhanced by the ability of Plx1 to cause calciumindependent activation of CaMKII. The results identify the targets of CaMKII and Plx1 that promote egg activation and define the first known pathway of CSF release in which an APC/C inhibitor is targeted for degradation only when both CaMKII and Plx1 are active after calcium elevation at fertilization. Conclusions: Plx1 with an intact polo-box domain is necessary for release of CSF arrest and sufficient when overexpressed. It acts at the same level as CaMKII in the pathway of calcium-induced CSF release by cooperating with CaMKII to regulate APC/C regulator(s), such as XErp1/Emi2, rather than by directly activating the APC/C itself.
Introduction
During vertebrate oocyte maturation, the immature oocyte develops into a fertilizable gamete arrested at second meiotic metaphase while awaiting fertilization. The mechanism of meiotic metaphase arrest has been studied for over 30 yr. In early studies, by microinjecting cytoplasm from a mature oocyte (unfertilized egg) into embryonic blastomeres, Masui and Markert found that the injected blastomere underwent cleavage arrest at the next mitosis [1] . Cytological analysis of the arrested blastomere revealed that the cell was arrested at metaphase, with a single metaphase spindle lacking centro-*Correspondence: jim.maller@uchsc.edu somes and resembling that seen at meiosis II. Masui and Markert named this cytoplasmic activity "cytostatic factor" (CSF). They further speculated that CSF was responsible for the meiotic arrest at metaphase II of vertebrate unfertilized eggs, and this hypothesis was supported by the finding that the CSF activity appeared during meiosis II and disappeared shortly after fertilization in response to elevated free Ca 2+ [1] . Recently, a substantial amount of evidence has suggested that regulation of anaphase-promoting complex/cyclosome (APC/C) is responsible for CSF arrest. The APC/C is a ubiquitin-protein isopeptide ligase (E3) composed of at least nine conserved subunits, and, in combination with a ubiquitin-activating enzyme (E1) and a ubiquitin carrier protein (E2 or UBC), it promotes ubiquitination and degradation of M phase regulators by the 26S proteasome at the metaphase-anaphase transition [2] [3] [4] . Of the three ubiquitination components, the APC/C is the only one whose activity clearly oscillates during the cell cycle. In vertebrates, the activity of the APC/C is regulated in several ways. One involves regulation of Fzy/Cdc20, which binds to the APC/C and activates it [5] . During arrest at metaphase by the spindle assembly checkpoint, the spindlecheckpoint protein Mad2 binds Fzy/Cdc20 to inhibit activation of the APC/C by Cdc20 [6] [7] [8] . In Xenopus egg extracts, overexpression of Xenopus Mad2 blocks calcium-induced CSF release, presumably by inhibiting APC/C-Fzy/Cdc20 activity [5] , and endogenous Mad2 is required for establishment of CSF arrest by Mos [9] . Another pathway contributing to CSF arrest is the cyclin E/Cdk2 pathway [10, 11] . This pathway is independent of the Mos/MAPK pathway and appears to also involve negative regulation of Fzy/Cdc20 because overexpression of Fzy/Cdc20 overcomes APC/C inhibition by cyclin E/Cdk2 (B. Grimison and J.M., unpublished data). Previously, it was reported that Early mitotic inhibitor 1 (Emi1), a vertebrate homolog of the Drosophila Rca 1 gene, is able to bind Cdc20, inhibit the activity of the APC/C, and cause a CSF-like arrest [12] [13] [14] . Depletion of Emi1 from CSF-arrested extracts was reported to cause spontaneous CSF release. However, this finding was challenged by a later report showing that Emi1 is not present in CSF-arrested cells at a level significant enough to participate in regulation of APC/C activity [15] , and Emi1-mediated M-phase arrest is unaffected by Ca 2+ , making it distinct from CSF arrest. In addition, during arrest with Emi1, both cyclins A and B are stabilized [13] , whereas during CSF arrest with Mos or cyclin E/Cdk2, only cyclin B is stabilized [16] [17] [18] [19] . A recent report identified a Xenopus Emi1-related protein, XErp1, that contains a Cdc20 binding domain closely related to that present in Emi1 [20] . Inactivation of XErp1, also called Emi2 and referred to as Emi2 hereafter in this paper, led to premature APC/C activation and CSF release, and addition of excess Emi2 to CSF extracts prevented release even in the presence of calcium [20] . Subsequent work showed that some antibodies to Emi1 also coimmunoprecipitate Emi2 [21] . This suggests that Emi2, not Emi1, is the relevant APC/C inhibitor involved in CSF arrest. Interestingly, Xenopus Polo-like kinase 1 (Plx1) phosphorylates Emi2 at sites that target it for degradation by the SCF pathway, hence promoting CSF release [20] .
The involvement of Plx1 in regulation of CSF arrest was initially suggested by the observation that the addition of kinase-dead Plx1 to CSF extracts blocked calcium-induced CSF release [22] [23] [24] , indicating a requirement for Plx1 activity in APC/C activation. This result was further supported by the finding that the metaphase-anaphase transition was blocked by immunodepletion of Plx1, and addition of recombinant Plx1 restored the transition [23] . The effect of Plx1 on CSF release requires an intact polo-box domain [24, 25] . It was suggested that rather than activating the APC/C directly, Plx1 might work by removing an inhibitor of the APC/C [23] . However, because Plx1 is fully active at metaphase [26] , it is unclear why Plx1-dependent phosphorylation effects would be restricted to anaphase. Under physiological conditions, CSF arrest is released upon fertilization, which causes a transient rise in the level of free calcium within the cell. In Xenopus cell-free extracts, the target of elevated calcium is calmodulin-dependent protein kinase II (CaMK II); specific inhibition of CaMK II prevented calcium-induced CSF release, and a constitutively active CaMK II mutant (CamCat) caused CSF release in extracts even in the absence of calcium [27] [28] [29] . Here, we report that Plx1 is a necessary component in the pathway of calciuminduced CSF release, and recombinant Plx1 protein is sufficient to trigger CSF release even in the absence of calcium. We also studied the relationship between Plx1 and CaMK II because each is necessary for CSF release and sufficient when overexpressed. It was found that Plx1 and CaMK II require each other in order to induce CSF release in the absence of calcium, and overexpression of Plx1 elevates calcium-independent activity of CaMK II. Further investigation showed that most likely both Plx1 and CaMK II achieve activation of the APC/C and CSF release through dual phosphorylation of Emi2 to promote its degradation.
Results
For this study, we generated two Xenopus Plx1 mutants in addition to wild-type Plx1 (see Figure S1 in the Supplemental Data available with this article online) [24] : Plx1NA, a kinase-dead Plx1 whose kinase activity is abolished by a N172A point mutation in its kinase domain [26] ; and Plx1WF, a kinase-active Plx1 with a W408F point mutation in its first polo box, a mutation equivalent to the W414F mutation in Plk1, which has been demonstrated to dramatically abolish the localization capability of the polo-box domain (PBD) [30] . This mutation also blocks the effects of Plx1 or Plx1NA on multiple mitotic steps, including CSF release, in Xenopus [24] . As described in the Experimental Procedures, the Plx1, Plx1NA, and Plx1WF proteins were expressed in insect cells and purified to homogeneity by a combination of affinity (Talon beads) and ion-exchange (Mono S) chromatography (see Supplemental Data). The recombinant proteins were highly concentrated, above 5 mg/ml as measured by the Bradford assay and quantification of stained gels.
Plx1
Causes CSF Release in the Absence of Calcium in a Polo-Box-Dependent Manner So far, all evidence based on loss of Plx1 function indicates that Plx1 is required for activating the proteolytic machinery for mitotic exit, but it has not been determined whether enhanced expression of Plx1 is sufficient to cause CSF release. In this study, active, highly purified Plx1 and the two Plx1 mutants were used in the Xenopus cell-free system to study the effects of Plx1 on mitotic exit. To Xenopus egg extracts arrested in metaphase by CSF we added recombinant Plx1 to a level 10-15-fold over the endogenous level and found that without the addition of calcium, Plx1 alone caused mitotic exit as judged by the degradation of cyclin B1 ( Figure 1A ) and histone H1 kinase activity (data not shown). The addition of the same amount of Plx1NA did not cause release, indicating Plx1 kinase activity is required for CSF release. It was noted that the CSF release caused by Plx1 was somewhat slower than that induced by calcium ( Figure 1A ), a result similar to that seen previously with release induced by CamCat in the absence of calcium [28] . This is consistent with evidence that several different pathways lead to APC/C inhibition and CSF arrest during oocyte maturation [31] , and presumably at egg fertilization/activation, multiple pathways act in concert to activate the APC/C and promote rapid CSF release.
We have previously shown that an intact PDB is required for Plx1 to function properly at multiple points during mitosis [24] . In particular, Plx1NA blocked calcium-induced CSF release, whereas Plx1NA with a W408F mutation in its first polo box did not block release. This suggested that Plx1NA was competing with endogenous Plx1 for PBD binding site(s), and this binding might be required for Plx1 to phosphorylate its substrate(s) and activate the proteolytic machinery. These results raise the question of whether Plx1-induced CSF release is also polo box dependent. To address this issue, we added Plx1WF to CSF-arrested Xenopus egg extracts; as predicted, the cyclin B1 level remained high even 80 min after the addition of Plx1WF ( Figure  1B ), whereas cyclin B1 was undetectable 40 min after the addition of wild-type Plx1, indicating the release of CSF activity. New cyclin synthesis restored cyclin B1 to its original level 80 min after Plx1 addition, indicating re-establishment of CSF arrest at the next M phase as expected. This result and previous evidence indicate that both inhibition and induction of CSF release by Plx1NA and Plx1, respectively, require a functional PBD.
The above results showed that Plx1 is sufficient to induce CSF release in a polo-box-dependent manner. It is unclear, however, whether Plx1 is part of the pathway by which calcium and CaMK II induce CSF release. To determine whether Plx1 is required for calciuminduced CSF release, we first completely immunodepleted endogenous Plx1 from metaphase-arrested Xenopus egg extracts (Figure 2A ). Upon calcium addition to the Plx1-depeleted extracts, the cyclin B1 level remained high even 40 min after calcium addition (Figure 2A) , whereas the same amount of calcium caused CSF release in mock-depleted extracts. It was noted that in the Plx1-depleted CSF extracts, the cyclin B1 level remained stable when no calcium was added, suggesting that Plx1 is not required for maintenance of CSF arrest.
To extend the above loss-of-function result and eliminate the potential codepletion of other important components, we performed rescue experiments. In separate experiments, we determined that the addition of recombinant Plx1 to CSF extracts to a level 2-fold over the endogenous level did not cause CSF release in the absence of calcium (data not shown). Therefore, to Plx1-depleted CSF extracts we added recombinant Plx1 to 2-fold over the undepleted endogenous level and observed restoration of calcium-induced CSF release ( Figure 2B ). As controls, the same level of recombinant Plx1 did not cause CSF release in the absence of calcium, and cyclin B remained stable in the Plx1-depleted extracts even when calcium was added (Figure 2B) . These results support the hypothesis [23] that Plx1 is a necessary component in the pathway of calcium-induced CSF release.
Plx1 and CamCat Require Each Other to Induce CSF Release in a Calcium-Independent Manner
Previously, it has been reported that CaMK II is required for calcium-induced CSF release [28] because inhibition of CaMK II blocks CSF release when calcium is added [27, 28] . Moreover, a calcium-independent constitutively active kinase fragment of CaMK II (CamCat) is sufficient to induce CSF release in a calcium-independent manner [28] . Because either Plx1 or CaMK II expression can induce CSF release, it is important to elucidate the relationship between these two kinases and, in particular, to determine whether they act in independent pathways or whether one is upstream of the other in the pathway of CSF release. To address this question, we first purified the constitutively active mutant of CaMK II (CamCat) and characterized its action in CSF extracts. As shown in Figure S2 , purified CamCat was added to CSF extracts at two final concentrations as indicated. At both final concentrations, CamCat was able to induce CSF release in the absence of calcium, consistent with a previous report [28] . For future experiments, a final concentration of 30 ng/l CamCat was used.
Because both Plx1 and CaMK II are necessary for CSF release, it is possible that they act in the same molecular pathway to control CSF release. In this case, if one kinase is upstream of another, depletion or inhibition of that kinase might block the ability of the other kinase to induce CSF release. It is also possible that both kinases act at the same level but need the activity of each other to pass the signal to downstream target(s), e.g., to phosphorylate their substrate(s). To distinguish between these possibilities, we first completely immunodepleted Plx1 from CSF extracts ( Figure  3A ) and then added CamCat at a concentration that causes spontaneous CSF release in mock-depleted extracts ( Figure 3A) . We also added calcium to one aliquot of the Plx1-depleted extract; although in this experiment some cyclin B degradation occurred, nuclear morphology verified that this was not sufficient to Next, we employed the CaMK II-specific inhibitor peptide, 281-309, to inhibit endogenous CaMK II activity [27] in order to evaluate whether Plx1 is able to trigger CSF release in the absence of CaMK II activity. As shown in Figure 3C , the inhibitor peptide 281-309 not only blocked calcium-induced CSF release as reported previously [27] but also inhibited the ability of Plx1 to induce CSF release. This latter event was surprising because it suggested that basal activity of CaMK II was necessary for Plx1-induced CSF release. To investigate this point further, we performed CaMK II assays in extracts by using a specific peptide substrate that encompasses the sequence around Thr286 in the autoregulatory region of CaMK II, which is associated with enzyme activation [32] . As shown in Figure 4 , calcium addition to a CSF extract led to rapid CaMK II activation, peaking at 1-2 min and returning to a sustained activity level above basal by 5 min. Studies of CaMK II in other systems have suggested the sustained activity of CaMK II long after a calcium stimulus reflects the activity of CaMK II phosphorylated at Thr286 [32] . These kinetics are similar to those reported previously for CaMK II during CSF release with a phosphospecific antibody to Thr286 [27] . Basal activity against the CaMK II substrate (inhibitable by the 281-309 peptide) was not detectable in a control extract, but remarkably, CaMK II activity was significantly generated upon addition of Plx1 ( (Figure 5A b ) . This result was also verified by sperm nuclear morphology ( Figure 5A, lower panel) . This result strongly suggests that neither Plx1 nor CaMK II promotes CSF release by directly activating the APC/C; rather, they most likely regulate the APC/C through activating regulator(s) such as Cdc20 or removing inhibitors that affect Cdc20-dependent activation. This concept is consistent with evidence that antisense ablation of Fzy/Cdc20 in maturing oocytes blocks egg activation (CSF release) by the calcium ionophore A23187 [33] and that the addition of antibody to Fzy/Cdc20 to CSF extracts blocks Ca 2+ -induced CSF release [5] . However, our study does not exclude the possibility that either kinase might phosphorylate subunits of the APC/C at sites that are insufficient for activation.
To further verify action through effects on Fzy/Cdc20, 
Combined Action of Plx1 and CamCat Overcomes Inhibition of CSF Release by Emi2 but Not by Mad2
If both Plx1 and CaMK II act in the same pathway on different components or on two independent pathways, then the combined action of both kinases might be sufficient to overcome arrest by either Mad2 or Emi2. We have shown that alone neither Plx1 nor CamCat is able to overcome Mad2 inhibition of the APC/C (Figure 5A b ) . Further work confirmed that Emi2 inhibits Fzy/Cdc20-APC/C activity in the presence of calcium, consistent with a previous report [20] . We found that Emi2 also inhibited CSF release induced by either Plx1 or CamCat ( Figure 6A) . However, as shown in Figure 6B , the combination of both kinases together did overcome the APC/C inhibition imposed by expression of Emi2 but not by Mad2, suggesting that no additional kinase activities are required to overcome inhibition of APC/C activation by Emi2. It has been demonstrated that the Plx1 phosphorylation-dependent degradation of Emi2 requires the PBD [20] . The PBD is thought to bind a phosphopeptide motif in target proteins under conditions in which a "priming kinase" has phosphorylated the substrate first to promote docking of the PBD, and this docking enhances subsequent Plx1-dependent phosphorylation [34, 35] . The fact that neither Plx1 nor CamCat alone was able to overcome the inhibition of Emi2 on the APC/C, whereas the combination of both kinases did overcome the inhibition, led us to suspect that CamCat might act as a priming kinase for Plx1 to generate a binding site for the PBD, leading to Plx1-dependent phosphorylation of Emi2 and facilitation of its degradation. To test our hypothesis, we carried out a series of in vitro phosphorylation reactions. First, GST-Emi2 was found to be a good substrate for CaMK II, whereas GST alone was only marginally phosphorylated ( Figure 6C ). Next, GST-Emi2 coupled to Dynabeads was initially phosphorylated by CaMK II in an assay with unlabeled ATP; after several washes of the complex, the GSTEmi2 was then incubated with Plx1 in the presence of [γ-32 P]ATP. It was found that phosphorylation of GSTEmi2 by Plx1 was clearly enhanced after pretreatment with CaMK II (Figure 6D, lower panel) . At this level of exposure, no phosphorylation of Emi2 by Plx1 is evident in the absence of prior phosphorylation by CaMK II. However, other experiments have confirmed that some Plx1-dependent phosphorylation of Emi2 can occur without CaMK II treatment under some conditions, as reported previously [20] . The increased autophosphorylation of Plx1 in the presence of Emi2 that had undergone priming phosphorylation by CaMK II ( Figure  6D ) may reflect loss of autoinhibition by the PBD when it binds a phosphomotif [36] . Importantly, in egg ex- tracts, Emi2 was degraded only when both Plx1 and CaMK II were active and able to cause CSF release ( Figure 6E ). This result strongly supports a model in which CaMK II acts as a priming kinase for Plx1 phosphorylation of Emi2 at sites that target it for degradation and presumably release of Fzy/Cdc20 for activation of the APC/C [20] .
Discussion
Several lines of evidence indicate that CSF activity is established by inhibition of the APC/C by multiple independent pathways [31] . It is evident that regulation of APC/C activity is also a key element in the maintenance and release of CSF arrest. Plx1 has previously been shown to be required for mitotic exit. In this report, we used the Xenopus cell-free system to demonstrate that Plx1 is not only necessary but also sufficient when overexpressed to trigger the metaphase-to-anaphase transition and CSF release. Wild-type recombinant Plx1 and a constitutively active mutant of Plx1 have been added to Xenopus CSF extracts previously, but no effect on maintenance of CSF arrest was evident after the addition (Y.-W. Qian, J.L., and J.L.M., unpublished data) . Now it is clear that this was due to insufficient expression levels, only about 3-fold over the endogenous level. In this study, we added highly purified recombinant Plx1 to CSF extracts at a final concentration of 10-15-fold over the endogenous Plx1 level and achieved CSF release even in the absence of calcium. This result suggests that a substrate of Plx1 normally not accessible to Plx1 before fertilization or calcium addition was phosphorylated by excess Plx1 because the kinase activity of Plx1 was required for CSF release. Moreover, an intact polo box of Plx1 was also shown to be required for Plx1 function, indicating that a PBD-mediated interaction regulates phosphorylation of the substrate. These results are consistent with the recent finding that Plx1 phosphorylates Emi2 and targets it for degradation, thereby relieving inhibition of the APC/C and promoting CSF release [20] . Although the involvement of Emi1 in CSF is controversial, it was also shown that Plx1 regulates the stability of Emi1 in a similar manner [37, 38] . In the case of Emi2, its interaction with Plx1 was shown to be polo box dependent, and depletion of Emi2 abolished the ability of Plx1NA to block calcium-induced CSF release [20] . However, this model raises a question. Because Plx1 activity is high during meiotic metaphase II arrest, why would a Plx1 substrate(s), e.g., Emi2, not be phosphorylated until after the addition of calcium? There are several possibilities. One explanation is that Plx1 and the substrate(s) are localized differentially, such that only when Plx1 is translocated to the site where the substrate(s) resides will the phosphorylation occur. Supporting evidence for this scenario comes from the translocation of Plx1 during mitosis, at which time Plx1 moves from centrosomes and spindle poles to the metaphase plate and finally to the midbody during cytokinesis [39, 40] . However, this cannot explain the requirement for Plx1 for CSF release (APC/C activation) in extracts without added DNA, where a mitotic spindle does not exist. This suggests a second possibility, that the polo-box-dependent interaction between Plx1 and its substrate(s) is dependent upon a third element. A plausible model involves a priming kinase. It has been reported that the PBD recognizes an optimal sequence containing Ser and Thr, and binding of the PBD to the motif may require phosphorylation by a priming kinase distinct from Plx1 itself [34, 35] . In support of this model, it has been reported that the interactions between Plx1 and Cdc25C [41] and between Plx1 and the checkpoint mediator protein Claspin [42] are PBDdependent and that binding of the PBD to Cdc25C or Claspin requires prior phosphorylation by a distinct priming kinase to generate a docking site for the PBD. In the case of regulation of CSF activity, it is possible that the phosphorylation of Plx1 substrate(s) also requires priming by a distinct kinase to generate a PBD binding site in the substrate itself (Figure 7 ) that brings the Plx1 catalytic domain into proximity with its substrate. Because the interaction between Plx1 and Emi2 is PBD-dependent and because CaMK II is required for Plx1 to induce CSF release, it seems likely that CaMK II may act as a priming kinase for phosphorylation of Emi2 to generate a docking site for the PBD, thereby promoting the Plx1-dependent phosphorylation of Emi2 at sites that target it for degradation, leading to activation of the APC/C and CSF release. This model gains strong support from the finding that CaMK II was able to phosphorylate Emi2 in vitro ( Figure 6C ) and that this phosphorylation in turn enhanced the ability of Plx1 to phosphorylate the APC/C inhibitor. Moreover, only the combined action of both kinases in extracts was able to cause degradation of Emi2 and overcome CSF arrest ( Figure 6E ). These results explain why Plx1 is needed for CSF release at anaphase even though the enzyme is fully active at metaphase during CSF arrest, and they also identify a key target of CaMK II for calcium-induced CSF release at fertilization.
However, neither Plx1 nor CamCat alone or the combination of both kinases was able to overcome inhibition of the APC/C by Mad2. Mad2 inhibits APC/C activity by binding to the positive APC/C regulator Fzy/ Cdc20. It has been reported that the binding of Mad2 to Fzy/Cdc20-APC/C is regulated by phosphorylation [43] , and phosphorylated Mad2 is unable to bind to Fzy/Cdc20. Although we found that both Plx1 and CaMK II were able to phosphorylate Mad2 in vitro to a certain extent (data not shown), phosphorylation by both kinases in CSF-arrested extracts did not relieve Mad2 inhibition of APC/C activation by Fzy/Cdc20, suggesting that another pathway is responsible for Mad2 phosphorylation/inactivation. It is notable that depletion of Mad2 does not trigger CSF release [9] , whereas depletion of Emi2 does cause release [20] , indicating that Emi2 is sufficient to inhibit Fzy/Cdc20 and maintain CSF arrest in the absence of calcium. Another pathway involved in CSF arrest is cyclin E/Cdk2, whose ability to inhibit the APC/C is removed by Tyr15 phosphorylation of Cdk2 after calcium addition [11] . It is possible the partial cyclin B degradation seen in some extracts in the absence of Plx1 (Figure 3A) , albeit not sufficient for M phase exit, reflects calcium-dependent inactivation of the Mad2 or cyclin E/Cdc2 APC/C inhibitory pathway.
It is clear that calcium-and CaMK II-induced CSF release requires Plx1, demonstrating that Plx1 is probably a physiological component of the CSF regulation machinery. In any case, a surprising result was that CSF release in response to Plx1 overexpression still requires CaMK II because the CaMK II inhibitory peptide blocked the effects of Plx1. The ability of Plx1 to ele- vate calcium-independent CaMK II activity explains why the inhibitor peptide 281-309 was able to block Plx1-dependent CSF release, and it reinforces the concept in our model (Figure 7 ) that Plx1 and CaMK II require each other to cooperate in relief of APC/C inhibition by Emi2. In addition to activation of CaMK II by calcium, it is evident that there is an apparent positive feedback loop between these kinases during CSF release, a loop in which Plx1 may promote elevated activity of CaMK II, which then phosphorylates Emi2 to promote PBD binding to Emi2 and elevation of Plx1 activity toward Emi2 (Figure 6 ). This positive feedback loop may contribute to the rapidity of APC/C activation at fertilization because Plx1 is already fully active at metaphase [26] .
Conclusions
Plx1 has been previously shown to be required for the metaphase-to-anaphase transition. Here, we have shown that overexpression of Plx1 alone is sufficient to trigger activation of the APC/C and release from CSF arrest. By studying the relationship between Plx1 and CaMK II, a kinase previously demonstrated also to be sufficient to trigger CSF release, we found that Plx1 and CaMK II are mutually dependent upon each other to induce CSF release. It is therefore evident that both Plx1 and CaMK II cooperate to promote activation of the APC/C and the release of CSF arrest. It was demonstrated that, rather than activating the APC/C directly, both Plx1 and CaMK II activate the complex by regulating Fzy/Cdc20. A plausible model involves CaMK II as a priming kinase to generate a docking site for PBD binding, which enables Plx1 to phosphorylate its substrate(s) and activate the APC/C. One candidate substrate is Emi2, whose interaction with Plx1 is PBDdependent and whose phosphorylation by Plx1 targets it for ubiquitin-mediated degradation. Our data show that phosphorylation of Emi2 by Plx1 is substantially enhanced if the substrate is prephosphorylated by CaMK II, and the combination of Plx1 and CamCat can overcome inhibition of CSF release by Emi2 by tar-geting it for degradation. The dual phosphorylation of Emi2 by Plx1 and CaMK II is further enhanced by the ability of Plx1 to activate CaMK II activity in a calciumindependent manner.
Experimental Procedures
Constructs and Protein Purification Plx1 and its mutants Plx1NA and Plx1WF were generated as described previously [24] . A baculovirus encoding a constitutively active fragment (amino acids 1-280) of CaMK II (CamCat) was a gift from M.D. Browning (Department of Pharmacology, UCHSC). The Plx1, Plx1NA, or Plx1WF proteins were purified with Talon beads, and this was followed by Mono S chromatography as described previously [26] . CamCat bearing a T7 tag was purified with a T7 Tag Affinity Purification Kit (Novagen) following the manufacturer's protocol. Emi2 was cloned by PCR amplifying the DNA from a Xenopus stage VI oocyte cDNA library (Stratagene) with the primers 5#-GACGACGACAAGATGGCAAATCTCTTAGAG-3# and 5#-GAGGA GAAGCCCGGTCTAGCTTCAAAGTCTC-3#, with subsequent cloning into the pET41 ek/LIC vector (Novagen) following the manufacturer's protocol. This vector produces a recombinant protein having both GST and 6His tags. GST-Emi2 was purified with Glutathione Sepharose 4B beads (Amersham Biosciences). The pET41 GST was prepared by cleaving a portion of GST-Emi2 on the Glutathione beads with thrombin protease (Amersham Biosciences). After several washes with PBS, GST was eluted from the beads with 10 mM glutathione (Sigma). P]ATP at 30°C for 10 min. The reaction was stopped by addition of 4× SDS gel sample buffer, electrophoresed on a 10% SDS-PAGE gel, and analyzed by autoradiography or immunoblotting. For CaMK II assay, the CaM Kinase II Assay Kit (Upstate) was used, and the manufacturer's protocol was followed. The autocamtide 2 substrate (KKALRRQETV-DAL) is based on the sequence around CaMK II's autoregulatory phosphorylation site (Thr286), which is associated with activation of calcium-independent CaMK II activity [32] . Other experiments demonstrated that Plx1 did not phosphorylate autocamtide 2 specifically, and Plx1 activity toward casein was not inhibited by the 281-309 peptide (data not shown).
In Vitro Phosphorylation

Preparation and Manipulation of CSF Extracts, Sperm
Nuclear Morphology, and Immunoblotting CSF extracts were prepared as described previously [44] . These extracts are arrested at metaphase of meiosis II with a high level of cyclin B/Cdc2 activity as a result of the activity of CSF. Upon the addition of calcium, the arrest is released, causing exit from metaphase and proteolysis of mitotic cyclins by the APC/C. Each individual reaction was made by transferring on ice 40 µl of extract into a 0.5 ml microcentrifuge tube containing about 8000 Xenopus sperm nuclei and then adding buffer or recombinant proteins to the following final concentrations unless otherwise indicated: 150 ng/ µl for Plx1, Plx1NA, or Plx1WF; 30 ng/µl for CamCat; and 120 ng/µl for Mad2. After a 10 min incubation on ice, CSF arrest was released by the addition of 0.4 µl of 50 mM CaCl 2 when applicable, and incubation was carried out at 21°C. Samples of 1 µl were taken at the indicated times, mixed with 4 µl of fixation/stain buffer (48% glycerol, 11% formaldehyde, 1× MMR [100 mM NaCl, 2 mM KCl, 1 mM MgSO 4 , 2 mM CaCl 2 , and 5 mM HEPES (pH 7.5)], and 1 µg/ ml DAPI), and sperm nuclei morphology was monitored by fluorescence microscopy. One microliter of sample at each time point was mixed with 20 µl of Laemmli Sample Buffer (BioRad) and boiled for 5 min. For immunoblotting, 10 µl of each sample, equivalent to 0.5 µl of extract, was used. Cyclins B1 and B2 were detected with sheep anti-cyclin B antibodies prepared as described previously [44] , and Emi2 was monitored with rabbit anti His-Emi2 (1-374) antibodies that were affinity purified on a column of GST-Emi2. 
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